1. Home
  2. FET vs OMER Comparison

FET vs OMER Comparison

Compare FET & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FET
  • OMER
  • Stock Information
  • Founded
  • FET 2005
  • OMER 1994
  • Country
  • FET United States
  • OMER United States
  • Employees
  • FET N/A
  • OMER N/A
  • Industry
  • FET Metal Fabrications
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • FET Industrials
  • OMER Health Care
  • Exchange
  • FET Nasdaq
  • OMER Nasdaq
  • Market Cap
  • FET 209.6M
  • OMER 226.0M
  • IPO Year
  • FET 2012
  • OMER 2009
  • Fundamental
  • Price
  • FET $15.87
  • OMER $3.92
  • Analyst Decision
  • FET
  • OMER Hold
  • Analyst Count
  • FET 0
  • OMER 2
  • Target Price
  • FET N/A
  • OMER N/A
  • AVG Volume (30 Days)
  • FET 77.8K
  • OMER 252.7K
  • Earning Date
  • FET 10-31-2024
  • OMER 11-07-2024
  • Dividend Yield
  • FET N/A
  • OMER N/A
  • EPS Growth
  • FET N/A
  • OMER N/A
  • EPS
  • FET N/A
  • OMER N/A
  • Revenue
  • FET $772,059,000.00
  • OMER N/A
  • Revenue This Year
  • FET $13.70
  • OMER N/A
  • Revenue Next Year
  • FET $3.17
  • OMER N/A
  • P/E Ratio
  • FET N/A
  • OMER N/A
  • Revenue Growth
  • FET 3.37
  • OMER N/A
  • 52 Week Low
  • FET $14.63
  • OMER $0.92
  • 52 Week High
  • FET $25.49
  • OMER $5.68
  • Technical
  • Relative Strength Index (RSI)
  • FET 43.04
  • OMER 48.63
  • Support Level
  • FET $14.63
  • OMER $3.54
  • Resistance Level
  • FET $18.14
  • OMER $4.23
  • Average True Range (ATR)
  • FET 0.58
  • OMER 0.21
  • MACD
  • FET -0.20
  • OMER 0.01
  • Stochastic Oscillator
  • FET 27.60
  • OMER 65.22

About FET Forum Energy Technologies Inc.

Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in three reporting segments, namely drilling and downhole which is also its key revenue generating segment, completions, and production. Revenue largely comes from consumable products and activity-based equipment. Consumable products include valves, centrifugal pumps, mud pump fluid end components, rig sensors among others.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: